Rocket Pharmaceuticals (RCKT) Restructuring Costs (2025)

Rocket Pharmaceuticals (RCKT) reported Restructuring Costs of -$68000.0 for Q4 2025, up 60.47% sequentially from -$172000.0 in Q3 2025.

Rocket Pharmaceuticals (RCKT) Restructuring Costs (2025) Analysis & Trends

Rocket Pharmaceuticals (RCKT) has 1 years of Restructuring Costs data on file, last reported at -$68000.0 in Q4 2025.

For the quarter ending Q4 2025, Restructuring Costs changed N/A year-over-year to -$68000.0; the trailing twelve-month figure through Dec 2025 stood at $3.2 million (changed N/A YoY), and the FY2025 full-year result was $3.2 million, changed N/A from the prior year.
Restructuring Costs improved to -$68000.0 in Q4 2025, from -$172000.0 in the prior quarter.
In the past five years, Restructuring Costs ranged from a high of $3.5 million in Q2 2025 to a low of -$172000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Rocket Pharmaceuticals	357.93 Mn	357.93 Mn	-

Download Data